Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma

BACKGROUND: Despite the high prevalence of epidermal growth factor receptor (EGFR) overexpression in head and neck squamous cell carcinomas (HNSCCs), incorporation of the EGFR inhibitor cetuximab into the clinical management of HNSCC has not led to significant changes in long-term survival outcomes....

Descripción completa

Detalles Bibliográficos
Autores principales: Espinosa-Cotton, Madelyn, Rodman III, Samuel N., Ross, Kathleen A., Jensen, Isaac J., Sangodeyi-Miller, Kenley, McLaren, Ayana J., Dahl, Rachel A., Gibson-Corley, Katherine N., Koch, Adam T., Fu, Yang-Xin, Badovinac, Vladimir P., Laux, Douglas, Narasimhan, Balaji, Simons, Andrean L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425573/
https://www.ncbi.nlm.nih.gov/pubmed/30890189
http://dx.doi.org/10.1186/s40425-019-0550-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425573/
https://www.ncbi.nlm.nih.gov/pubmed/30890189
http://dx.doi.org/10.1186/s40425-019-0550-z

Ejemplares similares